Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Taiwan Transition Period, Chinese SDA Open Opportunities To U.S. Exporters

This article was originally published in The Gray Sheet

Executive Summary

U.S. manufacturers exporting medical devices to Taiwan can bypass rigorous authentication procedures during the country's new regulation transition period, in effect until 2005, according to Asian market observers

You may also be interested in...



Global Device Market Barriers, Strategies Detailed For U.S. Trade Report

Increased medical equipment import tariffs of up to 51% within India's 2002-2003 budget will add millions of dollars in costs for U.S. device companies, AdvaMed asserts in a Dec. 13 statement to the Office of the U.S. Trade Representative

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel